Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Market Snapshot: Diabetic Macular Edema, Another Blockbuster Opportunity For Retinal Drugs?

Related Content

Alimera Resubmits Iluvien In U.S. As It Begins EU Launch

Mar 26 2013

Start-Ups, With An Eye On Success In Wet AMD, Tackle The Dry Form

Jun 25 2012

Challenging Lucentis: Eylea’s Early Progress Prompts $250 Mil.-$300 Mil. Sales Forecast For 2012

Feb 16 2012

Aerpio Obtains $27M In Series A To Fund Pair Of Phase II Studies

Aug 30 2012

Comparison Study Of Lucentis, Avastin And Eylea In DME Starts With NIH Funding

Aug 14 2012

Allergan Inks Two More Deals With Molecular Partners On New Approach To Ophthalmic Conditions

Aug 21 2012

Genentech Says <em>Lucentis</em> DME Product Will Ship Shortly

Aug 10 2012

Silence Therapeutics Raising $8.8M To Send RNAi Drug To Phase IIa

Jul 12 2012

Finally A FIBCO, Regeneron Sets Its Sights On <em>Eylea</em> And Beyond

Mar 26 2012

With Precedents In Place, GenSight Eyes Gene Therapies For Orphan Disorders

Apr 08 2013

U.K. Ophthalmology Spin-Out Raises £8m For DME Programs

Aug 22 2011

Related Companies

Iveric Bio, Inc.

Oxurion NV

Sesen Bio, Inc.

Bausch Health Companies Inc.

Bausch Health Companies Inc.

GenSight Biologics S.A.

Roche Holding AG

KalVista Pharmaceuticals, Inc.

Allergan plc

Vantia Therapeutics

Aerpio Pharmaceuticals, Inc.

Akebia Therapeutics, Inc.

Quark Pharmaceuticals, Inc.

Pfizer Inc.

Additional Topics

BioPharmaceutical

More from Archive

More from Pink Sheet

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window